On Air Now

Current Show

Coast to Coast AM   12:00 AM - 5:00 AM

Call Coast to Coast now at 1-800-825-5033

Show Info »

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 590 AM Kalamazoo, MI

Weather

Current Conditions(Kalamazoo,MI 49001)

More Weather »
63° Feels Like: 63°
Wind: NNW 12 mph Past 24 hrs - Precip: 0.12”
Current Radar for Zip

Tonight

Cloudy 60°

Tomorrow

Partly Cloudy 70°

Tues Night

Clear 51°

Alerts

Lundbeck says drug shows improvement in depression symptoms

COPENHAGEN (Reuters) - Danish pharmaceutical group Lundbeck and Japanese partner Takeda said on Saturday that data from clinical phase III studies with the antidepressant vortioxetine had shown significant improvement in patients' symptoms.

Lundbeck said in a statement that the trial showed safety levels consistent with previously completed studies at lower doses.

Lundbeck and Takeda submitted vortioxetine, also known as Brintellix, for regulatory approval in the United States and Europe at the end of last year.

Industry analysts at Deutsche Bank see the new drug having sales potential in excess of $1.5 billion and possibly up to $3 billion a year, although consensus forecasts for 2016 are a more modest $500 million, according to Thomson Reuters Pharma.

Lundbeck hopes the new drug will provide a new source of revenue as its existing antidepressant, Cipralex, sold as Lexapro in the United States and Japan, comes off patent protection.

(Reporting by Mette Fraende, Editing by Mark Trevelyan)

Comments